Drug name - Cosela
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8598186 | G1 THERAP | CDK inhibitors |
Oct, 2031
(9 years from now) | |
| US9957276 | G1 THERAP | CDK inhibitors |
Oct, 2031
(9 years from now) | |
| US10189849 | G1 THERAP | CDK inhibitors |
Oct, 2031
(9 years from now) | |
| US8598197 | G1 THERAP | CDK inhibitors |
Oct, 2031
(9 years from now) | |
| CN104045654A | G1 THERAP | Cdk Inhibitor |
Jun, 2017
(5 years ago) | |
| CN106967074A | G1 THERAP | Cdk Inhibitor |
Mar, 2020
(2 years ago) | |
| CN106008533A | G1 THERAP | Cdk Inhibitor |
Oct, 2031
(9 years from now) | |
| CN106008533B | G1 THERAP | Cdk Inhibitor |
Oct, 2031
(9 years from now) | |
| CN103936745A | G1 THERAP | Cdk Inhibitor |
Oct, 2031
(9 years from now) | |
| CN103429243A | G1 THERAP | Cdk Inhibitor |
Oct, 2031
(9 years from now) | |
| CN103936745B | G1 THERAP | Cdk Inhibitor |
Oct, 2031
(9 years from now) | |
| CN103429243B | G1 THERAP | Cdk Inhibitor |
Oct, 2031
(9 years from now) | |
| IN307331B | G1 THERAP | Pyrrolopyrimidine Fused Piperazinone Compounds As Cdk Inhibitors |
Oct, 2031
(9 years from now) | |
| IN201303795P4 | G1 THERAP | Cdk Inhibitors |
Oct, 2031
(9 years from now) | |
| EP2632467B1 | G1 THERAP | Cdk Inhibitors |
Oct, 2031
(9 years from now) | |
| EP3381920A1 | G1 THERAP | Cdk Inhibitors |
Oct, 2031
(9 years from now) | |
| EP3118203A1 | G1 THERAP | Cdk Inhibitors |
Oct, 2031
(9 years from now) | |
| EP2632467A1 | G1 THERAP | Cdk Inhibitors |
Oct, 2031
(9 years from now) | |
| EP3381920B1 | G1 THERAP | Cdk Inhibitors |
Oct, 2031
(9 years from now) | |
| EP3567042B1 | G1 THERAP | Cdk Inhibitors |
Oct, 2031
(9 years from now) | |
| EP3118203B1 | G1 THERAP | Cdk Inhibitors |
Oct, 2031
(9 years from now) | |
| EP2632467A4 | G1 THERAP | Cdk Inhibitors |
Oct, 2031
(9 years from now) | |
| EP3567042A1 | G1 THERAP | Cdk Inhibitors |
Oct, 2031
(9 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10189850 | G1 THERAP | CDK inhibitors |
Oct, 2031
(9 years from now) | |
| US10927120 | G1 THERAP | CDK inhibitors |
Oct, 2031
(9 years from now) | |
| US10085992 | G1 THERAP | Transient protection of normal cells during chemotherapy |
Mar, 2034
(11 years from now) | |
| US10966984 | G1 THERAP | Transient protection of normal cells during chemotherapy |
Mar, 2034
(11 years from now) | |
| US11040042 | G1 THERAP | Transient protection of normal cells during chemotherapy |
Mar, 2034
(11 years from now) | |
| US9487530 | G1 THERAP | Transient protection of normal cells during chemotherapy |
Mar, 2034
(11 years from now) | |
Drugs and Companies using TRILACICLIB DIHYDROCHLORIDE ingredient
Treatment: A method to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a carboplatin and etoposide-containing regimen for extensive-stage small cell lung cancer; A method to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen for extensive-stage small cell lung cancer; a method to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a topotecan-containing regimen for extensive- stage small cell lung cancer
Dosage: POWDER;INTRAVENOUS
| Strength | Dosage | Availability |
|---|---|---|
| EQ 300MG BASE/VIAL | POWDER;INTRAVENOUS | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.